

Art Unit: 1648

Claims 7, 8, and 10 have been cancelled.

In claim 11, "claim 10, which is defined by" has been changed to "5, wherein the nucleic acid encoding the fusion monomer comprises".

Claims 12 and 13 have been cancelled.

In claim 14, "nonhuman" has been inserted before "host", and "or 12" has been deleted.

In claim 15, "A vaccine" has been changed to "An immunogenic composition", and "the homopentamer of claim 7," has been deleted.

In claim 16, "vaccine" has been changed to "immunogenic composition".

In claim 17, "vaccine" has been changed to "immunogenic composition".

In claim 18, "vaccine" has been changed to "immunogenic composition".

TS
3/10/09
of
A In claim 19, "vaccine" has been changed to "immunogenic composition", and "any one of claims 15 to 17 or the host of claim 14" has been changed to "of claim 15".

Claim 20 has been cancelled.

The following is an examiner's statement of reasons for allowance:

The prior art recognized pentameric mucous membrane binding proteins such as cholera toxin B or E. coli heat-labile enterotoxin B as being good carriers for immunogenic peptides. The prior art also recognized a problem in assembling pentamers for some fusions, see the discussion in Liljequist et al (cited in IDS). However, the prior art did not teach or suggest the inventor's solution to this problem,